Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002:22:35-8.

Adverse reactions to OsteoSet bone graft substitute, the incidence in a consecutive series

Gregory H Lee  1 , Joseph G Khoury, John-Erik Bell, Joseph A Buckwalter
Affiliations

Adverse reactions to OsteoSet bone graft substitute, the incidence in a consecutive series

Gregory H Lee et al. Iowa Orthop J. 2002.

Abstract

Background: The purpose of this study was to identify factors that may be associated with the development of a sterile inflammatory reaction to OsteoSet (Wright Medical Technology) bone graft substitute. We report on a series of 58 consecutive cases of patients with benign bone lesions who developed an adverse reaction to Osteoset. All procedures were performed by a single orthopaedic oncology surgeon.

Methods: Patients who exhibited an adverse reaction to OsteoSet and those who did not were analyzed for statistical differences with respect to age, sex, volume of graft material used, size of pellet, use of alcohol washes, mixing of OsteoSet with allograft, medications, drug allergies, and smoking history. Comparisons were made between the reaction group and the non-reaction group with respect to the these variables.

Results: Eight definite (13.8%) and 3 probable (5.2%) reactions were identified. Symptoms developed an average of 38.9 days after the operation. There was no statistically significant difference (p>0.05) in the volume of Osteoset used, size of pellet, use of alcohol washes, mixing of OsteoSet with allograft, patient age, sex, drug allergies, or smoking history. Reported use of at least one medication was statistically significant between groups when probable reactions were included with the non-reaction group (p < 0.05), but not when probables were analyzed with the definite reaction group ( p < 0.10). A review of our patients' medication lists did not reveal any single or combination of medications likely to be responsible for this difference. Type and location of tumor also did not appear to differ significantly between the two groups.

Conclusions: Although we report a 13.8%-19.0% incidence of adverse reaction to OsteoSet, we are unable to identify any statistically significant factors that might predict the development of a reaction. Fortunately, the reaction is essentially self limited and fairly benign requiring only anti-inflammatories and observation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Damien CJ, Parsons JR. Bone graft and bone graft substitutes: a review of current technology and applications. Journal of Applied Biomaterials. 1991;2(3):187–203. - PubMed
    1. Mirzayan R, Panossian V, Avedian R, Forrester DM, Menendez LR. The use of calcium sulfate in the treatment of benign bone lesions: a preliminary report. Journal of Bone and Joint Surgery. 2001;83-A(3):355–358. - PubMed
    1. Robinson D, Alk D, Sandbank J, Farber R, Halperin N. Inflammatory reactions associated with a calcium sulfate bone substitute. Annals of Transplantation. 1999;4(3-4):91–97. - PubMed
    1. Kelly CM, Wilkins RM, Gitelis S, Hartjen C, Watson JT, Kim PT. The use of surgical grade calcium sulfate as a bone graft substitute: results of a multicenter trial. Clinical Orthopaedics and Related Research. 2001;382:42–50. - PubMed
    1. Gitelis S, Piasecki P, Turner T, Haggard W, Charters J, Urban R. Use of calcium sulfate-based bone graft substitute for benign bone lesions. Orthopedics. 2001;24(2):162–166. - PubMed

LinkOut - more resources